Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARTH: Rosuvastatin for Early Prevention of Atheroma Progression
NCT02105623Phase 4Terminated
- Start
- Jun 2014
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rosuvastatin in coronary arteriosclerosis (2 arms). Primary endpoint: Percent change in total atheroma volume at 2 years. Started Jun 2014; status: terminated.
02
Drugs
rosuvastatin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NCT02105623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105623.